Table 1 Baseline characteristics

Number of patients

95

29

Epidemiological findings

 Age at conception, years

33.0 [29.1, 35.0]

33.0 [31.0, 36.0]

0.17

 BMI

19.8 [18.6, 21.3]

20.4 [18.1, 23.4]

0.52

 Duration of SLE (days)

2614 [1514, 4985]

2548 [1003, 4277]

0.58

 Smoking history (%)

10 (10.5)

2 (6.9)

0.73

 Previous spontaneous abortion (%)

16 (16.8)

8 (27.6)

0.31

 Previous anti-hypertensive medication use (%)

1 (1.1)

5 (17.2)

 < 0.01

 Multiparous (%)

34 (36.6)

11 (37.9)

1.00

 Infertility treatment (%)

22 (23.2)

8 (27.6)

0.81

 Any flare at conception (%)

1 (1.4)

5 (19.2)

 < 0.01

 Remission at conception (%)

46 (65.7)

13 (50.0)

0.24

Organ manifestation

 Joint/muscular manifestation (%)

59 (62.1)

20 (69.0)

0.65

 Skin/mucocutaneous manifestation (%)

70 (73.7)

17 (58.6)

0.19

 Renal manifestation (%)

17 (17.9)

15 (51.7)

 < 0.01

 Lupus nephritis class III/IV (%)

6 (6.3)

6 (20.7)

0.053

 Serositis (%)

17 (17.9)

8 (27.6)

0.38

 Neurological manifestation (%)

8 (8.4)

2 (6.9)

1.00

 Hematological manifestation (%)

79 (83.2)

21 (72.4)

0.31

Immunological findings

 Anti-dsDNA Ab (%)

61 (64.2)

24 (82.8)

0.098

 Anti-RNP Ab (%)

22 (36.7)

8 (42.1)

0.888

 Anti-Sm Ab (%)

28 (31.5)

8 (29.6)

1.00

 Anti-Ro/SSA Ab (%)

55 (59.1)

21 (72.4)

0.29

 Anti-La/SSB Ab (%)

13 (21.7)

0 (0.0)

0.032

 LAC (%)

9 (9.8)

4 (13.8)

0.51

 Anti-CL Ab (%)

21 (23.1)

6 (21.4)

1.00

 Anti-CLβ2GPI Ab (%)

13 (14.0)

2 (6.9)

0.52

 Low C3 (%)

55 (59.1)

18 (62.1)

0.94

 Low C4 (%)

69 (74.2)

22 (75.9)

1.00